Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.

Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.

Item
http://www.wikidata.org/entity/Q37762683
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinomaSurvival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer modelOvarian cancer: emerging molecular-targeted therapies.Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian CancerEffect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis.Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study.A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
P2860

Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.

Item
http://www.wikidata.org/entity/Q37762683
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@en
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@nl
type
label
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@en
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@nl
prefLabel
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@en
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Residual cancer stem cells aft ...... t outcomes for ovarian cancer.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921